Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer

Lung Cancer

Volumn 52, Issue 3, 2006, Pages 327-332

  Leighl, Natasha B ^a   Goss, G D ^b   Lopez, P G ^c   Burkes, R L ^d   Dancey, J E ^a   Rahim, Y H ^e   Rudinskas, L C ^f   Pouliot, J F ^g   Rodgers, A ^g   Pond, G R ^a   Shepherd, F A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c Northeastern Ontario Regional Cancer Centre   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO EAST GENERAL HOSPITAL   (Canada)

^f HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^g INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Caelyx; Liposomal doxorubicin; Refractory lung cancer; Relapsed lung cancer; Second line chemotherapy; Small cell lung cancer

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DYSPHAGIA; EPIGASTRIC PAIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; LUNG SMALL CELL CANCER; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; STOMATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SURVIVAL RATE; VINCRISTINE;

EID: 33646379346     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.02.006     Document Type: Article

References (28)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics. CA Cancer J Clin 55 March-April (2) (2005) 74-108
2. Souhami R.L., and Law K. Longevity in small cell lung cancer. Br J Cancer 61 (1990) 584-589
3. Arriagada R., Kramar A., Le Chevalier T., and De Cremoux H. Competing events determining relapse-free survival in limited small-cell carcinoma: the French Cancer Centers' Lung Group. J Clin Oncol 10 (1992) 447-451
4. Postmus P.E., and Smit E.F. Treatment of relapsed small cell lung cancer. Semin Oncol 28 2 Suppl. 4 (2001) 48-52
5. Shepherd F.A., Evans W.K., MacCormick R., Feld R., and Yau J.C. Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin resistant small cell lung cancer. Cancer Treat Rep 71 (1987) 941-944
6. Perez-Soler R., Glisson B.S., Lee J.S., Fossella F.V., Murphy W.K., Shin D.M., et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14 (1996) 2785-2790
7. Von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658-667
8. Doxil™ investigator's brochure. Menlo Park, CA: SEQUUS Pharmaceuticals, Inc.; May 1996.
9. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16 (1998) 2445-2451
10. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
11. Ranson M.R., Carmichael J., O'Byrne K., Stewart S., Smith D., and Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15 (1997) 185-191
12. Samantas E., Kalofonos H., Linardou H., Nicolaides C., Mylonakis N., Fountzilas G., et al. et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small cell lung cancer. Ann Oncol 11 (2000) 1395-1397
13. Leighl N.B., Burkes R.L., Dancey J.E., Lopez P.G., Higgins B.P., David Walde P.L., et al. A Phase I study of pegylated liposomal doxorubicin hydrochloride (CAELYX™) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Clin Lung Cancer 5 (2003) 107-112
14. National Cancer Institute of Canada Clinical Trials Group. Expanded common toxicity criteria (December 1994)
15. Sculier J.P., Klastersky J., Libert P., Ravez P., Brohee D., Vandermoten G., et al. A phase II study evaluating CAV (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 6 (1990) 110-118
16. Davies A.M., Evans W.K., Mackay J.A., and Shepherd F.A. Treatment of recurrent small cell lung cancer. Hematol Oncol Clin N Am 18 (2004) 387-416
17. O'Bryan R.M., Crowley J.J., Kim P.N., Epstein R.B., Neilan B., Coltman Jr. C.A., et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine and cyclophosphamide for salvage treatment in small cell lung cancer. Cancer 54 (1990) 856-860
18. von Pawel J., Gatzemeier U., Pujol J.L., Moreau L., Bildat S., Ranson M., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19 (2001) 1743-1749
19. O'Brien M., Ciuleanu T., Tsekov H., Shparyk Y., Cucevic B., Juhasz G., et al. Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC. Lung Cancer 49 Suppl. 2 (2005) S54 [abstr O-157]
20. Masuda N., Fukuoka M., Kusonoki Y., Matsui K., Takifuji N., Kudoh S., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 (1992) 1225-1229
21. Masters G.A., Declerck L., Blank C., Sandler A., DeVore R., Miller K., et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer. Eastern Cooperative Group Trial 1597. J Clin Oncol 21 (2003) 1550-1555
22. Schuette W., Nagel S., Juergens S., Bork I., Wollschlaeger B., Schaedlich S., et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 7 (2005) 133-137
23. Stathopoulos G.P., Christodoulou C., Stathopoulos J., Skarlos D., Rigatos S.K., Giannakakis T., et al. Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer Chemother Pharmacol September (2005) 1-5
24. Kelley M.J., Linnoila R.I., Avis I.L., Georgiadis M.S., Cutitta F., Mulshine J.L., et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112 (1997) 256-261
25. Fidias P., and Lynch Jr. T.J. Targeted therapy of SCLC using N901-blocked ricin. Clin Lung Cancer 3 (2002) 219-222
26. Dy G.K., Miller A.A., Mandrekar S.J., Aubry M.C., Langdon Jr. R.M., Morton R.F., et al. A phase II trial of imatinib (STI571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16 (2005) 1811-1816
27. Krug L.M., Crapanzano J.P., Azzoli C.G., Miller V.A., Rizvi N., Gomez J., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103 (2005) 2128-2131
28. Rudin C., Otterson G.A., Mauer A.M., Villalona-Calero M.A., Tomek R., Prange B., et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13 (2002) 539-545